With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class ...
Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback